Market capitalization | $814.66m |
Enterprise Value | $306.89m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.30 |
P/S ratio (TTM) P/S ratio | 6.11 |
P/B ratio (TTM) P/B ratio | 1.52 |
Revenue growth (TTM) Revenue growth | -5.41% |
Revenue (TTM) Revenue | $133.35m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Prothena Corp. Plc forecast:
10 Analysts have issued a Prothena Corp. Plc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 133 133 |
5%
5%
|
|
Gross Profit | 116 116 |
13%
13%
|
|
EBITDA | -151 -151 |
44%
44%
|
EBIT (Operating Income) EBIT | -168 -168 |
49%
49%
|
Net Profit | -132 -132 |
80%
80%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Gene Kinney |
Employees | 173 |
Founded | 1969 |
Website | www.prothena.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.